Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis.

Grunwald VV, Hentrich M, Schiel X, Dufour A, Schneider S, Neusser M, Subklewe M, Fiegl M, Hiddemann W, Spiekermann K, Rothenberg-Thurley M, Metzeler KH.

Blood Adv. 2019 Sep 24;3(18):2696-2699. doi: 10.1182/bloodadvances.2019000265. No abstract available.

2.

Cluster Analysis According to Immunohistochemistry is a Robust Tool for Non-Small Cell Lung Cancer and Reveals a Distinct, Immune Signature-defined Subgroup.

Sterlacci W, Fiegl M, Juskevicius D, Tzankov A.

Appl Immunohistochem Mol Morphol. 2019 May 1. doi: 10.1097/PAI.0000000000000751. [Epub ahead of print]

PMID:
31058655
3.

Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.

Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.

Leukemia. 2018 Dec;32(12):2558-2571. doi: 10.1038/s41375-018-0268-9. Epub 2018 Oct 1.

4.

Diagnostic and prognostic impact of mucin 1-6 expression in non-small cell lung cancer.

Sterlacci W, Fiegl M, Veits L, Tzankov A.

Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):187-191. doi: 10.4103/IJPM.IJPM_678_17.

5.

MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.

Sterlacci W, Fiegl M, Gugger M, Bubendorf L, Savic S, Tzankov A.

Virchows Arch. 2017 Jul;471(1):49-55. doi: 10.1007/s00428-017-2131-1. Epub 2017 May 20.

PMID:
28528511
6.

Antifungal prophylaxis in newly diagnosed AML patients-Adherence to guidelines and feasibility in a real life setting.

Berking S, Doedens D, Horns H, Fiegl M, Ostermann H, Rieger CT.

Mycoses. 2017 Sep;60(9):600-606. doi: 10.1111/myc.12635. Epub 2017 May 15.

PMID:
28504318
7.

A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.

Sandhöfer N, Metzeler KH, Kakadia PM, Pasalic Z, Hiddemann W, Neusser M, Steinlein O, Fiegl M, Subklewe M, Spiekermann K, Bohlander SK, Schneider S, Braess J.

Genes Chromosomes Cancer. 2017 Aug;56(8):632-638. doi: 10.1002/gcc.22466. Epub 2017 May 19.

PMID:
28420034
8.

Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.

Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, Hiddemann W, Braess J, Spiekermann K; AMLCG Study Group.

Blood. 2016 Aug 4;128(5):686-98. doi: 10.1182/blood-2016-01-693879. Epub 2016 Jun 10.

9.

Reply.

Kocher F, Lunger F, Seeber A, Amann A, Pircher A, Hilbe W, Fiegl M.

Clin Lung Cancer. 2016 Sep;17(5):e187. doi: 10.1016/j.cllc.2016.04.008. Epub 2016 May 7. No abstract available.

PMID:
27245293
10.

Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung.

Sterlacci W, Fiegl M, Droeser RA, Tzankov A.

Pathobiology. 2016;83(5):267-75. doi: 10.1159/000444804. Epub 2016 May 27.

11.

Microenvironmental oxygen partial pressure in acute myeloid leukemia: Is there really a role for hypoxia?

Rieger CT, Fiegl M.

Exp Hematol. 2016 Jul;44(7):578-82. doi: 10.1016/j.exphem.2016.04.008. Epub 2016 Apr 23. Review.

PMID:
27118044
12.

Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung.

Sterlacci W, Saker S, Huber B, Fiegl M, Tzankov A.

Virchows Arch. 2016 Apr;468(4):463-71. doi: 10.1007/s00428-015-1900-y. Epub 2016 Jan 27.

PMID:
26818832
13.

Reactivation of polyomavirus in the genitourinary tract is significantly associated with severe GvHD and oral mucositis following allogeneic stem cell transplantation.

Peterson L, Ostermann H, Fiegl M, Tischer J, Jaeger G, Rieger CT.

Infection. 2016 Aug;44(4):483-90. doi: 10.1007/s15010-016-0872-4. Epub 2016 Jan 20.

PMID:
26792012
14.

Weight Loss and Decrease of Body Mass Index during Allogeneic Stem Cell Transplantation Are Common Events with Limited Clinical Impact.

Rieger CT, Wischumerski I, Rust C, Fiegl M.

PLoS One. 2015 Dec 18;10(12):e0145445. doi: 10.1371/journal.pone.0145445. eCollection 2015.

15.

IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia.

Kuett A, Rieger C, Perathoner D, Herold T, Wagner M, Sironi S, Sotlar K, Horny HP, Deniffel C, Drolle H, Fiegl M.

Sci Rep. 2015 Dec 17;5:18411. doi: 10.1038/srep18411.

16.

Microenvironmental hypoxia regulates FLT3 expression and biology in AML.

Sironi S, Wagner M, Kuett A, Drolle H, Polzer H, Spiekermann K, Rieger C, Fiegl M.

Sci Rep. 2015 Nov 30;5:17550. doi: 10.1038/srep17550.

17.

Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.

Wagner M, Oelsner M, Moore A, Götte F, Kuhn PH, Haferlach T, Fiegl M, Bogner C, Baxter EJ, Peschel C, Follows GA, Ringshausen I.

Blood. 2016 Jan 28;127(4):436-48. doi: 10.1182/blood-2015-05-646935. Epub 2015 Oct 27.

18.

Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.

Aschauer G, Greil R, Linkesch W, Nösslinger T, Stauder R, Burgstaller S, Fiegl M, Fridrik M, Girschikofsky M, Keil F, Petzer A.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):e143-9. doi: 10.1016/j.clml.2015.07.645. Epub 2015 Aug 5.

PMID:
26422252
19.

Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis.

Kocher F, Lunger F, Seeber A, Amann A, Pircher A, Hilbe W, Fiegl M.

Clin Lung Cancer. 2016 Jan;17(1):62-7.e1. doi: 10.1016/j.cllc.2015.08.006. Epub 2015 Aug 22.

PMID:
26420370
20.

NSCLC without Antineoplastic Treatment: Incidence, Characteristics, and Outcome as Outlined in the TYROL Study.

Kocher F, Lunger F, Pircher A, Hilbe W, Fiegl M.

Oncology. 2015;89(5):255-61. doi: 10.1159/000433544. Epub 2015 Aug 18.

PMID:
26303584
21.

Routine Use of Bendamustine in Patients with Chronic Lymphocytic Leukemia: An Observational Study.

Ninkovic M, Fiegl M, Mian M, Mondello P, Kocher F, Waldthaler C, Verdorfer I, Steurer M, Gastl G, Pircher A.

Anticancer Res. 2015 Sep;35(9):5129-39.

PMID:
26254418
22.

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.

Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. Epub 2015 Aug 4.

PMID:
26239198
23.

Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study).

Hilbe W, Pall G, Kocher F, Pircher A, Zabernigg A, Schmid T, Schumacher M, Jamnig H, Fiegl M, Gächter A, Freund M, Kendler D, Manzl C, Zelger B, Popper H, Wöll E.

PLoS One. 2015 May 28;10(5):e0125364. doi: 10.1371/journal.pone.0125364. eCollection 2015.

24.

Hypoxia regulates proliferation of acute myeloid leukemia and sensitivity against chemotherapy.

Drolle H, Wagner M, Vasold J, Kütt A, Deniffel C, Sotlar K, Sironi S, Herold T, Rieger C, Fiegl M.

Leuk Res. 2015 Jul;39(7):779-85. doi: 10.1016/j.leukres.2015.04.019. Epub 2015 May 7.

PMID:
25982178
25.

Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics.

Pomme G, Augustin F, Fiegl M, Droeser RA, Sterlacci W, Tzankov A.

Virchows Arch. 2015 Jul;467(1):55-66. doi: 10.1007/s00428-015-1767-y. Epub 2015 Apr 9.

PMID:
25854914
26.

Liver Transplantation-Associated Lung Cancer: Comparison of Clinical Parameters and Outcomes.

Kocher F, Finkenstedt A, Fiegl M, Graziadei I, Gamerith G, Oberaigner W, Vogel W, Hilbe W.

Clin Lung Cancer. 2015 Sep;16(5):e75-81. doi: 10.1016/j.cllc.2015.02.003. Epub 2015 Feb 17.

PMID:
25783479
27.

Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.

Augustin F, Fiegl M, Schmid T, Pomme G, Sterlacci W, Tzankov A.

J Clin Pathol. 2015 May;68(5):368-73. doi: 10.1136/jclinpath-2014-202819. Epub 2015 Mar 2. Erratum in: J Clin Pathol. 2015 May;68(5):doi:10.1136/jclinpath-2014-202819corr1.

PMID:
25731190
28.

Cardiovascular Comorbidities and Events in NSCLC: Often Underestimated but Worth Considering.

Kocher F, Fiegl M, Mian M, Hilbe W.

Clin Lung Cancer. 2015 Jul;16(4):305-12. doi: 10.1016/j.cllc.2014.12.007. Epub 2014 Dec 30.

PMID:
25659438
29.

Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.

Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, Auberger J, Nevinny-Stickel M, Sterlacci W, Tzankov A, Jamnig H, Kohler K, Zabernigg A, Frötscher J, Oberaigner W, Fiegl M.

Lung Cancer. 2015 Feb;87(2):193-200. doi: 10.1016/j.lungcan.2014.12.006. Epub 2014 Dec 18.

PMID:
25564398
30.

Applicability of the EORTC/MSG criteria for IFD in clinical practice.

Rieger H, Lustig D, Barlow S, Ostermann H, Fiegl M, Peterson L, Rieger CT.

Ann Hematol. 2015 May;94(5):847-55. doi: 10.1007/s00277-014-2282-y. Epub 2014 Dec 30.

PMID:
25544029
31.

The bone marrow microenvironment is a critical player in the NK cell response against acute myeloid leukaemia in vitro.

Vasold J, Wagner M, Drolle H, Deniffel C, Kütt A, Oostendorp R, Sironi S, Rieger C, Fiegl M.

Leuk Res. 2015 Feb;39(2):257-62. doi: 10.1016/j.leukres.2014.12.001. Epub 2014 Dec 9.

PMID:
25542695
32.

Non-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.

Wasle I, Gamerith G, Kocher F, Mondello P, Jaeger T, Walder A, Auberger J, Melchardt T, Linkesch W, Fiegl M, Mian M.

Ann Hematol. 2015 Apr;94(4):593-601. doi: 10.1007/s00277-014-2250-6. Epub 2014 Nov 13.

PMID:
25387663
33.

B cell lymphoma with lung involvement: what is it about?

Mian M, Wasle I, Gritsch S, Willenbacher W, Fiegl M.

Acta Haematol. 2015;133(2):221-5. doi: 10.1159/000365778. Epub 2014 Nov 4.

PMID:
25376208
34.

A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma.

Mian M, Marcheselli L, Rossi A, Visco C, Chiappella A, Volpetti S, Zaja F, Mondello P, Fiegl M, Billio A, Federico M, Luminari S, Rambaldi A, Cortelazzo S.

Ann Oncol. 2014 Dec;25(12):2398-404. doi: 10.1093/annonc/mdu462. Epub 2014 Oct 1.

PMID:
25274614
35.

Platelets promote mitochondrial uncoupling and resistance to apoptosis in leukemia cells: a novel paradigm for the bone marrow microenvironment.

Velez J, Enciso LJ, Suarez M, Fiegl M, Grismaldo A, López C, Barreto A, Cardozo C, Palacios P, Morales L, Duque JE, Carmona JU, Konopleva M, Andreeff M, Samudio I.

Cancer Microenviron. 2014 Aug;7(1-2):79-90. doi: 10.1007/s12307-014-0149-3. Epub 2014 Aug 12.

36.

Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).

Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M, Eckmayr J, Schmid T, Hilbe W, Fiegl M, Greil R.

Lung Cancer. 2014 Sep;85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3.

PMID:
25043642
37.

Increased suicide risk in cancer patients in Tyrol/Austria.

Oberaigner W, Sperner-Unterweger B, Fiegl M, Geiger-Gritsch S, Haring C.

Gen Hosp Psychiatry. 2014 Sep-Oct;36(5):483-7. doi: 10.1016/j.genhosppsych.2014.05.017. Epub 2014 Jun 2.

PMID:
25015541
38.

R-CHOP versus R-COMP: are they really equally effective?

Mian M, Wasle I, Gamerith G, Mondello P, Melchardt T, Jäger T, Linkesch W, Fiegl M.

Clin Oncol (R Coll Radiol). 2014 Oct;26(10):648-52. doi: 10.1016/j.clon.2014.05.012. Epub 2014 Jun 12.

PMID:
24929649
39.

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.

Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K.

Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. Epub 2014 May 9.

40.

A success story: how a single targeted-therapy molecule impacted on treatment and outcome of diffuse large B-cell lymphoma.

Mian M, Augustin F, Kocher F, Gunsilius E, Willenbacher W, Zabernigg A, Zangerl G, Oexle H, Schreieck S, Schnallinger M, Fiegl M.

Anticancer Res. 2014 May;34(5):2559-64.

PMID:
24778077
41.

Small steps of improvement in small-cell lung cancer (SCLC) within two decades: a comprehensive analysis of 484 patients.

Fiegl M, Pircher A, Waldthaler C, Gamerith G, Kocher F, Pall G, Nevinny M, Schmid T, Sterlacci W, Jamnig H, Zangerl G, Zabernigg A, Oberaigner W, Hilbe W.

Lung Cancer. 2014 May;84(2):168-74. doi: 10.1016/j.lungcan.2014.02.005. Epub 2014 Feb 17.

PMID:
24646832
42.

Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.

Pircher A, Manzl C, Fiegl M, Popper H, Pirker R, Hilbe W.

Lung Cancer. 2014 Mar;83(3):408-10. doi: 10.1016/j.lungcan.2013.12.007. Epub 2013 Dec 25.

PMID:
24412619
43.

Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization.

Sterlacci W, Savic S, Fiegl M, Obermann E, Tzankov A.

J Thorac Oncol. 2014 Jan;9(1):41-9. doi: 10.1097/JTO.0000000000000021.

44.

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.

Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. Epub 2013 Dec 3.

45.

Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients.

Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, Skrabs C, Zabernigg A, Schmid F, Haslbaur F, Winder G, Walder A, Lang A, Voskova D, Greil R, Mayer J, Gastl G; Austrian Collaborative Study Group on Alemtuzumab in Chronic Lymphocytic Leukemia, in cooperation with The Czech Leukemia Study Group for Life, CELL.

Ann Hematol. 2014 Feb;93(2):267-77. doi: 10.1007/s00277-013-1966-z. Epub 2013 Nov 30.

PMID:
24292560
46.

Physiological hypoxia prevents bile salt-induced apoptosis in human and rat hepatocytes.

Hohenester S, Vennegeerts T, Wagner M, Wimmer R, Drolle H, Rieger C, Denk GU, Rust C, Fiegl M.

Liver Int. 2014 Sep;34(8):1224-31. doi: 10.1111/liv.12368. Epub 2013 Nov 20.

PMID:
24164780
47.

Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.

Fiegl M, Unterhalt M, Kern W, Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Schöndube D, Serve H, Reichle A, Hentrich M, Schiel X, Sauerland C, Heinecke A, Rieger C, Beelen D, Berdel WE, Büchner T, Hiddemann W; German AML Cooperative Group (AMLCG).

Leukemia. 2014 May;28(5):1001-7. doi: 10.1038/leu.2013.297. Epub 2013 Oct 22.

PMID:
24150216
48.

Rituximab: how evidence based medicine can change our clinical practice.

Mian M, Gritsch S, Wasle I, Zabernigg A, Fiegl M.

Leuk Lymphoma. 2014 Jul;55(7):1694-6. doi: 10.3109/10428194.2013.853302. Epub 2014 Feb 4. No abstract available.

PMID:
24138329
49.

Docetaxel in the treatment of non-small cell lung cancer (NSCLC) -- an observational study focusing on symptom improvement.

Pircher A, Wasle IK, Mian M, Gamerith G, Ulsperger E, Studnicka M, Mohn-Staudner A, Hilbe W, Fiegl M.

Anticancer Res. 2013 Sep;33(9):3831-6.

PMID:
24023316
50.

Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study).

Mian M, Capello D, Ventre MB, Grazio D, Svaldi M, Rossi A, Tsang R, Gospodarowicz MK, Oldani E, Federico M, Luminari S, Marcheselli L, Pogliani EM, Rossini F, Cabrera ME, Martelli M, Gutierrez-Garcia G, Busetto M, Visco C, Fiegl M, Rossi D, Gaidano G, Cavalli F, Zucca E, Rambaldi A, Cortelazzo S; International Extranodal Lymphoma Study Group (IELSG).

Ann Hematol. 2014 Feb;93(2):221-231. Epub 2013 Aug 20.

PMID:
23959436

Supplemental Content

Support Center